B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation

Cancer Science

Volumn 107, Issue 7, 2016, Pages 944-954

  Chen, Xinran ^a   Wang, Ling ^a   Wang, Wei ^a,b   Zhao, Lianmei ^a   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; B7 H4; cell proliferation; esophageal squamous cell carcinoma; IL 6 STAT3 signal pathway

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 2; PROTEIN BAX; PROTEIN BCL 2; STAT3 PROTEIN; SURVIVIN; TOCILIZUMAB; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOPLASM; DRUG EFFECT; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGEAL TISSUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SQUAMOUS CELL CARCINOMA CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 84978818538     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12949     Document Type: Article

References (34)

1. Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249–58.
2. Henry MA, Lerco MM, Ribeiro PW et al. Epidemiological features of esophageal cancer: squamous cell carcinoma versus adenocarcinoma. Acta Cir Bras 2014; 29: 389–93.
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. Natl Cancer Inst 2005; 97: 142–6.
4. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17: 2–9.
5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241–52.
6. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007; 17: 38–44.
7. Ajani JA, Barthel JS, Bentrem DJ et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011; 9: 830–87.
8. Dong H, Zhu G, Tamada K et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365–9.
9. Wang S, Zhu G, Chapoval AI et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 2000; 96: 2808–13.
10. Chapoval AI, Ni J, Lau JS et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269–74.
11. Sica GL, Choi IH, Zhu G et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849–61.
12. Tseng SY, Otsuji M, Gorski K et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839–46.
13. Brandt CS, Baratin M, Yi EC et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206: 1495–503.
14. Prasad DV, Richards S, Mai XM et al. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003; 18: 863–73.
15. Zang X, Loke P, Kim J et al. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 2003; 100: 10388–92.
16. Sun Y, Wang Y, Zhao J et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006; 53: 143–51.
17. Fauci JM, Straughn JM Jr, Ferrone S et al. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol 2012; 127: 420–5.
18. Zang X, Thompson RH, Al-Ahmadie HA et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 2007; 104: 19458–63.
19. Quandt D, Fiedler E, Boettcher D et al. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res 2011; 7: 3100–11.
20. Arigami T, Uenosono Y, Ishigami S et al. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg 2011; 35: 2051–7.
21. Mugler KC, Singh M, Tringler B et al. Expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol 2007; 15: 363–70.
22. Jung SG, Choi KU, Lee SD et al. The relationship between B7-H4 expression and clinic pathological characteristics in clinical stage T1 conventional renal cell carcinoma. Korean J Urol 2011; 52: 90–5.
23. Chen LJ, Sun J, Wu HY et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother 2011; 60: 1047–55.
24. He C, Qiao H, Jiang H et al. The inhibitory role of B7-H4 in antitumor immunity: association with cancer progression and survival. Clin Dev Immunol 2011; 2011: 695834.
25. Cheng L, Jiang J, Gao R et al. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 2009; 19: 1481–6.
26. Qian Y, Hong B, Shen L et al. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell Tissue Res 2013; 353: 139–51.
27. Demaria M, Camporeale A, Poli V. STAT3 and metabolism: how many ways to use a single molecule? Int J Cancer 2014; 135: 1997–2003.
28. Dvorak K, Chavarria M, Payne CM et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bileacids and low pH: relevance to Barrett's Esophagus. Clin Cancer Res 2007; 13: 5305–13.
29. Kryczek I, Zou L, Rodriguez P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871–81.
30. Kryczek I, Wei S, Zhu G et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67: 8900–5.
31. Peng HX, Wu WQ, Yang DM et al. Role of B7-H4 siRNA in proliferation, migration, and invasion of LOVO colorectal carcinoma cell line. Biomed Res Int 2015; 2015: 326981.
32. Abroun S, Saki N, Ahmadvand M et al. STATs: an old story. Yet mesmerizing. Cell J 2015; 17: 395–411.
33. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61: 5137–44.
34. Jeon H, Vigdorovich V, Garrett-thomson SC et al. Stucture and cancer immunotherpy of the B7 family membrane B7x. Cell Rep 2014; 9: 1089–98.